- cafead Apr 02, 2020 at 12:02: AM
via Bristol Myers Squibb's top shareholders offered advice to the company as to how it should revise its executive compensation in light of the company's $74 billion merger with Celgene. As a result of those discussions, the value of CEO Giovanni Caforio's dipped slightly to $18.8 million, as both his short-term and long-term incentives were tied to a successful integration.
article source
article source